Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Effect of an endothelin-receptor antagonist on ischemic acute renal failure.

Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW.

Am J Physiol. 1994 Jan;266(1 Pt 2):F135-8.

PMID:
8304480
2.
4.

Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Yano M, Ikemoto F.

Eur J Pharmacol. 1992 Oct 6;221(1):77-83.

PMID:
1459192
5.

In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure.

Nakamoto M, Shapiro JI, Shanley PF, Chan L, Schrier RW.

J Clin Invest. 1987 Sep;80(3):698-705.

6.

Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.

Zhang Y, Oliver JR, Horowitz JD.

Cardiovasc Res. 1998 Sep;39(3):665-73.

PMID:
9861310
7.

ETA-dependent pressor effects and release of prostacyclin induced by endothelins in pulmonary and renal vasculature.

D'Orléans-Juste P, Yano M, Télémaque S.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S235-8.

PMID:
7509954
8.

The effect of verapamil on renal function after warm and cold ischemia in the isolated perfused rat kidney.

Shapiro JI, Cheung C, Itabashi A, Chan L, Schrier RW.

Transplantation. 1985 Dec;40(6):596-600.

PMID:
4071610
9.
10.

Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.

Wellings RP, Corder R, Warner TD, Cristol JP, Thiemermann C, Vane JR.

Br J Pharmacol. 1994 Feb;111(2):515-20.

11.

Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs.

Brooks DP, dePalma PD, Gellai M, Nambi P, Ohlstein EH, Elliott JD, Gleason JG, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1994 Nov;271(2):769-75.

PMID:
7965795
12.
13.

Therapeutic administration of an endothelin-A receptor antagonist after acute ischemic renal failure dose-dependently improves recovery of renal function.

Knoll T, Schult S, Birck R, Braun C, Michel MS, Bross S, Juenemann KP, Kirchengast M, Rohmeiss P.

J Cardiovasc Pharmacol. 2001 Apr;37(4):483-8.

PMID:
11300661
14.

Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation.

Pollock DM, Opgenorth TJ.

Am J Physiol. 1993 Jan;264(1 Pt 2):R222-6.

PMID:
8430883
15.

Protection from renal ischemia reperfusion injury by an endothelin-A receptor antagonist BQ-123 in relation to nitric oxide production.

Erdogan H, Fadillioglu E, Emre MH.

Toxicology. 2006 Dec 7;228(2-3):219-28. Epub 2006 Sep 8.

PMID:
17046139
16.
17.

Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065.

Wellings RP, Warner TD, Thiemermann C, Cristol JP, Corder R, Vane JR.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S103-6.

PMID:
7509915
18.

BQ-123, a specific endothelin (ETA) receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation.

Büyükgebiz O, Aktan AO, Haklar G, Yalçin AS, Yeğen C, Yalin R, Ercan ZS.

Transpl Int. 1996;9(3):201-7.

PMID:
8723187
19.

Effects of endothelins on renin secretion from rat kidneys.

Scholz H, Krämer BK, Hamann M, Götz KH, Kurtz A.

Acta Physiol Scand. 1995 Oct;155(2):173-82.

PMID:
8669290
20.

The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(a) receptor antagonist in men.

Schmidt A, Bayerle-Eder M, Pleiner H, Zeisner C, Wolzt M, Mayer G, Schmetterer L.

Nitric Oxide. 2001 Aug;5(4):370-6.

PMID:
11485375

Supplemental Content

Support Center